Body Composition: The relative amounts of various components in the body, such as percentage of body fat.Absorptiometry, Photon: A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION.Recombinant Fusion Proteins: Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Muscle Strength: The amount of force generated by MUSCLE CONTRACTION. Muscle strength can be measured during isometric, isotonic, or isokinetic contraction, either manually or using a device such as a MUSCLE STRENGTH DYNAMOMETER.Bone Resorption: Bone loss due to osteoclastic activity.Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Membrane Fusion: The adherence and merging of cell membranes, intracellular membranes, or artificial membranes to each other or to viruses, parasites, or interstitial particles through a variety of chemical and physical processes.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Single-Chain Antibodies: A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Immunoglobulin Variable Region: That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.Interleukin-2: A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Epitopes: Sites on an antigen that interact with specific antibodies.Tumor Necrosis Factor Ligand Superfamily Member 15: A member of tumor necrosis factor superfamily found on ENDOTHELIAL CELLS that plays a role in the inhibition of endothelial cell growth and PHYSIOLOGIC ANGIOGENESIS.OX40 Ligand: A membrane-bound tumor necrosis family member that is expressed on activated antigen-presenting cells such as B-LYMPHOCYTES and MACROPHAGES. It signals T-LYMPHOCYTES by binding the OX40 RECEPTOR.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Receptors, OX40: A tumor necrosis family receptor with specificity for OX40 LIGAND. It is found on the surface of activated T-LYMPHOCYTES where it plays a role in enhancing cytokine production and proliferation of CD4-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Ligands: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)Mast Cells: Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR.Cell Degranulation: The process of losing secretory granules (SECRETORY VESICLES). This occurs, for example, in mast cells, basophils, neutrophils, eosinophils, and platelets when secretory products are released from the granules by EXOCYTOSIS.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.Receptors, IgE: Specific molecular sites on the surface of B- and T-lymphocytes which combine with IgEs. Two subclasses exist: low affinity receptors (Fc epsilon RII) and high affinity receptors (Fc epsilon RI).Allergy and Immunology: A medical specialty concerned with the hypersensitivity of the individual to foreign substances and protection from the resultant infection or disorder.Action Potentials: Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli.Receptors, Tumor Necrosis Factor: Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.Fushi Tarazu Transcription Factors: Fushi tarazu transcription factors were originally identified in DROSOPHILA. They are found throughout ARTHROPODS and play important roles in segmentation and CENTRAL NERVOUS SYSTEM development.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Databases, Genetic: Databases devoted to knowledge about specific genes and gene products.Genome, Human: The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs.TNF Receptor-Associated Factor 1: A signal transducing tumor necrosis factor receptor associated factor that is involved in TNF RECEPTOR feedback regulation. It is similar in structure and appears to work in conjunction with TNF RECEPTOR-ASSOCIATED FACTOR 2 to inhibit APOPTOSIS.Tumor Necrosis Factors: A family of proteins that were originally identified by their ability to cause NECROSIS of NEOPLASMS. Their necrotic effect on cells is mediated through TUMOR NECROSIS FACTOR RECEPTORS which induce APOPTOSIS.Fagopyrum: A plant genus of the family POLYGONACEAE that is used as an EDIBLE GRAIN. Although the seeds are used as cereal, the plant is not one of the cereal grasses (POACEAE).Recombinant Proteins: Proteins prepared by recombinant DNA technology.Medical Staff: Professional medical personnel who provide care to patients in an organized facility, institution or agency.Satiety Response: Behavioral response associated with the achieving of gratification.Glucose Metabolism Disorders: Pathological conditions in which the BLOOD GLUCOSE cannot be maintained within the normal range, such as in HYPOGLYCEMIA and HYPERGLYCEMIA. Etiology of these disorders varies. Plasma glucose concentration is critical to survival for it is the predominant fuel for the CENTRAL NERVOUS SYSTEM.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Day Care: Institutional health care of patients during the day. The patients return home at night.Tumor Necrosis Factor-alpha: Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.Astragalus membranaceus: A plant species of the Astragalus genus which is source of Huang qi preparation used in TRADITIONAL CHINESE MEDICINE.Interleukin-6: A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.Cytokines: Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.Receptors, Tumor Necrosis Factor, Type I: A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.

Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. (1/48)

Natural killer cells mediate spontaneously secretory/necrotic killing against rare leukemia cell lines and a nonsecretory/apoptotic killing against a large variety of tumor cell lines. The molecules involved in nonsecretory/apoptotic killing are largely undefined. In the present study, freshly isolated, nonactivated, human NK cells were shown to express TNF, lymphotoxin (LT)-alpha, LT-beta, Fas ligand (L), CD27L, CD30L, OX40L, 4-1BBL, and TNF-related apoptosis-inducing ligand (TRAIL), but not CD40L or nerve growth factor. Complementary receptors were demonstrated to be expressed on the cell surface of solid tumor cell lines susceptible to apoptotic killing mediated by NK cells. Individually applied, antagonists of TNF, LT-alpha1beta2, or FasL fully inhibited NK cell-mediated apoptotic killing of tumor cells. On the other hand, recombinant TNF, LT-alpha1beta2, or FasL applied individually or as pairs were not cytotoxic. In contrast, a mixture of the three ligands mediated significant apoptosis in tumor cells. These findings demonstrate that human NK cells constitutively express several of the TNF family ligands and induce apoptosis in tumor cells by simultaneous engagement of at least three of these cytotoxic molecules.  (+info)

CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. (2/48)

Primary CD30(+) cutaneous T-cell lymphomas (CTCLs) represent a spectrum of non-Hodgkin's lymphomas (NHLs) that have been well defined at the clinical, histologic, and immunologic level. This group, which includes 2 main entities (large cell lymphoma and lymphomatoid papulosis [LyP]) and borderline cases, is characterized by the expression of CD30 antigen by neoplastic large cells at presentation, possible spontaneous regression of the skin lesions, and generally favorable clinical course. Although the functional relevance of CD30 and its natural ligand (CD30L) expression in most cases of NHL is presently undefined, previous studies indicate that CD30L is likely to mediate reduction of proliferation in CD30(+) anaplastic large-cell NHL. No information is currently available concerning the expression of CD30L in primary CD30(+) CTCLs. In this study, we investigated the immunophenotypic and genotypic expression of CD30 and CD30L in different developmental phases of skin lesions (growing v spontaneously regressing). By immunohistochemistry, CD30L expression was detected in regressing lesions only; by molecular analysis, the expression of CD30L was clearly higher in regressing lesions than in growing ones. CD30L, while expressed by some small lymphocytes, was most often coexpressed by CD30(+) neoplastic large cells, as demonstrated by 2-color immunofluorescence and by immunohistochemistry on paraffin sections. Taken together, these data suggest that CD30-CD30L interaction may play a role in the pathobiology of primary cutaneous CD30(+) lymphoproliferative disorders. In particular, CD30L (over)expression might have a major role in the mechanism of self-regression of skin lesions, the most distinctive clinical feature of this cutaneous lymphoma subtype.  (+info)

Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. (3/48)

Infection of inbred mouse strains with Leishmania major is a well characterized model for analysis of T helper (Th)1 and Th2 cell development in vivo. In this study, to address the role of costimulatory molecules CD27, CD30, 4-1BB, and OX40, which belong to the tumor necrosis factor receptor superfamily, in the development of Th1 and Th2 cells in vivo, we administered monoclonal antibody (mAb) against their ligands, CD70, CD30 ligand (L), 4-1BBL, and OX40L, to mice infected with L. major. Whereas anti-CD70, anti-CD30L, and anti-4-1BBL mAb exhibited no effect in either susceptible BALB/c or resistant C57BL/6 mice, the administration of anti-OX40L mAb abrogated progressive disease in BALB/c mice. Flow cytometric analysis indicated that OX40 was expressed on CD4(+) T cells and OX40L was expressed on CD11c(+) dendritic cells in the popliteal lymph nodes of L. major-infected BALB/c mice. In vitro stimulation of these CD4(+) T cells showed that anti-OX40L mAb treatment resulted in substantially reduced production of Th2 cytokines. Moreover, this change in cytokine levels was associated with reduced levels of anti-L. major immunoglobulin (Ig)G1 and serum IgE. These results indicate that anti-OX40L mAb abrogated progressive leishmaniasis in BALB/c mice by suppressing the development of Th2 responses, substantiating a critical role of OX40-OX40L interaction in Th2 development in vivo.  (+info)

Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. (4/48)

CD153 (CD30 ligand) is a member of the TNF ligand/cytokine family expressed on the surface of human B cells. Upon exposure to IL-4, a critical Ig class switch-inducing cytokine, Ag-activated T cells express CD30, the CD153 receptor. The observation that dysregulated IgG, IgA, and/or IgE production is often associated with up-regulation of T cell CD30 prompted us to test the hypothesis that engagement of B cell CD153 by T cell CD30 modulates Ig class switching. In this study, we show that IgD+ IgM+ B cells up-regulate CD153 in the presence of CD154 (CD40 ligand), IL-4, and B cell Ag receptor engagement. In these cells, CD153 engagement by an agonistic anti-CD153 mAb or T cell CD30 inhibits S mu-->Sgamma, Smu-->Salpha, and S mu-->Sepsilon class switch DNA recombination (CSR). This inhibition is associated with decreased TNFR-associated factor-2 binding to CD40, decreased NF-kappaB binding to the CD40-responsive element of the Cgamma3 promoter, decreased Igamma3-Cgamma3 germline gene transcription, and decreased expression of Ku70, Ku80, DNA protein kinase, switch-associated protein-70, and Msh2 CSR-associated transcripts. In addition, CD153 engagement inhibits IgG, IgA, and IgE production, and this effect is associated with reduced levels of B lymphocyte maturation protein-1 transcripts, and increased binding of B cell-specific activation protein to the Ig 3' enhancer. These findings suggest that CD30+ T cells modulate CSR as well as IgG, IgA, and IgE production by inducing reverse signaling through B cell CD153.  (+info)

CD30L up-regulates CD30 and IL-4 expression by T cells. (5/48)

CD30L is frequently expressed on acute myeloid leukemia (AML) blasts. Its presence is associated with the co-expression of interleukin-4 (IL-4) receptor and with the expansion of specific T-helper 2 (Th2) cell subsets producing IL-4 and expressing CD30. Recombinant CD30L-bearing cells up-regulated the expression of surface CD30 and increased the production of IL-4 and soluble (s) CD30 by co-cultured T cells. These findings were confirmed with AML blasts expressing surface CD30L, where blocking anti-CD30 antibodies completely abolished the release of sCD30 and reduced the production of IL-4. Our data indicates a direct role of CD30L(+) neoplastic cells in driving the immune response toward a Th2-polarized non-protective state.  (+info)

Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. (6/48)

A number of different immunotoxins composed of cell-specific targeting structures coupled to plant or bacterial toxins have increasingly been evaluated for immunotherapy. Because these foreign proteins are highly immunogenic in humans, we have developed a new CD30 ligand-based fusion toxin (Ang-CD30L) using the human RNase angiogenin. The completely human fusion gene was inserted into a pET-based expression plasmid. Transformed Escherichia coli BL21(DE3) were grown under osmotic stress conditions in the presence of compatible solutes. After isopropyl beta-D-thiogalactoside induction, the M(r) 37,000 His(10)-tagged Ang-CD30L was directed into the periplasmic space and functionally purified by a combination of metal ion affinity followed by enterokinase cleavage of the His(10)-Tag and molecular size chromatography. The characteristics of the recombinant protein were assessed by ELISA, flow cytometry, and toxicity assays showing specific activity against CD30(+) Hodgkin-derived cells. Specific binding activity of Ang-CD30L was verified by competition with anti-CD30 monoclonal antibody Ki-4 and commercially available CD30L-CD8 chimeric protein. Ang-CD30L showed RNase activity in vitro. The human recombinant immunotoxin showed significant toxicity toward several CD30-positive cell lines (HDLM-2, L1236, KM-H2, and L540Cy) and exhibited highest cytotoxicity against L540 cells (IC(50) = 8 ng/ml) as determined by cell proliferation assays. CD30 specificity was confirmed by competitive toxicity assays. This is the first report on the specific cytotoxicity of a recombinant completely human fusion toxin with possibly largely reduced immunogenicity for the treatment of CD30-positive malignancies.  (+info)

Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population. (7/48)

CD30-CD30 ligand (CD30L) signal transduction appears to protect against autoimmune diabetes by preventing expansion of autoreactive T cells and suppressing Th1-cytokine response. The purpose of this study was to determine whether CD30 or CD30L genes serve as a novel susceptibility gene for type 1 diabetes in humans. We screened CD30 and CD30L genes for polymorphisms in Japanese patients with type 1 diabetes and control subjects. Then, association studies were performed between each of the identified polymorphisms and type 1 diabetes. Direct-sequencing analysis of the CD30 and CD30L genes revealed four polymorphisms: one in the CD30 gene (-201G/A from the transcription start site), and three in the CD30L gene [CA repeat in the promoter, 276G/A in the exon 3, -73T/C in the intron 3 (IVS3 -73T/C)]. Association studies revealed no association between the CD30 and CD30L genes and type 1 diabetes in the whole population. In the female and male subpopulations, however, the frequency of (CA)(9) allele of the CD30L gene promoter or T allele of IVS3 -73T/C polymorphism in the CD30L gene was slightly higher in female patients with type 1 diabetes than that in control females. In conclusion, we could not find significant association between CD30 or CD30L genes and type 1 diabetes, but (CA)(9) allele in the promotor or T allele of -73T/C in intron 3 in CD30L gene might play a minor role in the pathogenesis of type 1 diabetes, only in the Japanese female population.  (+info)

Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. (8/48)

CD30 is up-regulated in several human diseases and viral infections but its role in immune regulation is poorly understood. Here, we report the expression of a functional soluble CD30 homologue, viral CD30 (vCD30), encoded by ectromelia (mousepox) virus, a poxvirus that causes a severe disease related to human smallpox. We show that vCD30 is a 12-kD secreted protein that not only binds CD30L with high affinity and prevents its interaction with CD30, but it also induces reverse signaling in cells expressing CD30L. vCD30 blocked the generation of interferon gamma-producing cells in vitro and was a potent inhibitor of T helper cell (Th)1- but not Th2-mediated inflammation in vivo. The finding of a CD30 homologue encoded by ectromelia virus suggests a role for CD30 in antiviral defense. Characterization of the immunological properties of vCD30 has uncovered a role of CD30-CD30L interactions in the generation of inflammatory responses.  (+info)

*Paolo Casali

Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human ...

*CD30

"Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the ... CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells. CD30 is the target of the FDA approved ... Granados S, Hwang ST (Jun 2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases". The ... and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation". ...

*Cytokine

... and includes several other non-cytokine ligands like CD40, CD27 and CD30, besides the ligands on which the family is named (TNF ...

*Cytokine receptor

... and includes several other non-cytokine ligands like receptors, CD40, CD27 and CD30, besides the ligands on which the family is ... Arimont A, Sun S, Smit MJ, Leurs R, de Esch IJ, de Graaf C (2017). "Structural Analysis of Chemokine Receptor-Ligand ...

*TRAF5

... and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation". ... a new member of the EPLG gene family encoding ligands of EPH-related protein-tyrosine kinase receptors". Genomics. 41 (1): 17- ... TRAF5 has been shown to interact with: ASK1, CD134, CD30, CD40, RANK TNFRSF13B, and TNFRSF14. GRCh38: Ensembl release 89: ... 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry. 272 (4): 2042-5. doi: ...

*LAG3

... 's main ligand is MHC class II, to which it binds with higher affinity than CD4. The protein negatively regulates cellular ... "Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ...

*List of MeSH codes (D23)

... cd40 ligand MeSH D23.101.100.110.281 --- cytokine receptor gp130 MeSH D23.101.100.110.283 --- fms-like tyrosine kinase 3 MeSH ... cd30 MeSH D23.050.301.264.035.131 --- antigens, cd31 MeSH D23.050.301.264.035.134 --- antigens, cd34 MeSH D23.050.301.264. ... cd40 ligand MeSH D23.050.301.264.035.281 --- cytokine receptor gp130 MeSH D23.050.301.264.035.282 --- e-selectin MeSH D23.050. ... cd30 MeSH D23.101.100.110.131 --- antigens, cd31 MeSH D23.101.100.110.134 --- antigens, cd34 MeSH D23.101.100.110.136 --- ...

*Adult T-cell leukemia/lymphoma

... of ATL patients have disease expressing CD30. This suggests treatment with CD30-targeting brentuximab vedotin may be beneficial ... and receptor activator of nuclear factor-κB ligand (RANKL) have been associated with hypercalcemia. Immunodeficient mice that ... Campuzano-Zuluaga, G; Pimentel, A; Diaz, L; Chapman-Fredricks, JR; and Ramos, JC " CD30 Expression Is Associated With Decreased ...

*MAPK/ERK pathway

August 2003). "MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that ... Receptor-linked tyrosine kinases such as the epidermal growth factor receptor (EGFR) are activated by extracellular ligands. ...
Rollinghoff, M; Pfizenmaier, K; and Wagner, H, "T-t cell interactions during cytotoxic t cell responses. IV. Murine lymphoid dendritic cells are powerful stimulators for helper t-lymphocytes." (1982). Subject Strain Bibliography 1982. 2724 ...
The article is a survey of the cellular interactions in the humoral response to antigen, the role of the major histocompatibility complex in the response, and the antibody response to antigens under the control of histocompatibility-linked immune response (Ir) genes. The article includes chapters on hapten-carrier effects and on the role of the major histocompatibility complex in T- and B-cell co-operation. Furthermore, macrophage-T-cell interactions, T-T cell interactions, and T-cell-macrophage-B-Cell interactions are discussed. There are 84 references.
CD40L / CD154 antibody [YMF323.6.2] (CD40 ligand) for FACS, WB. Anti-CD40L / CD154 mAb (GTX42386) is tested in Human, Rhesus Monkey, Cynomolgus monkey samples. 100% Ab-Assurance.
Gentaur molecular products has all kinds of products like :search , Reliatech \ Anti_Mouse, mab TNFSF6 Source Rat \ 103-M495 for more molecular products just contact us
Tnfsf11 - Tnfsf11 (untagged) - Mouse tumor necrosis factor (ligand) superfamily, member 11 (Tnfsf11), (10ug) available for purchase from OriGene - Your Gene Company.
Hi Horse Pals ~ Erica sent us this beautiful story to share with all of our Horse Pals! We hope you enjoy it as much as we did! Thanks for sharing it, Erica! @raya and @very Ya gotta meet Molly... photos by Pam Kaster Meet Molly.Shes a grey speckled pony who was abandoned by her owners when Hurricane Katrina hit southern Louisiana . She spent weeks on her own before finally being rescued and taken to a farm where abandoned animals were stockpiled. While there, she was attacked by a pit bull terrier and almost died. Her gnawed right front leg became infected, and her vet went to LSU for help, but LSU was overwhelmed, and this pony was a welfare case. You know how that goes. But after surgeon Rustin Moore met Molly, he changed his mind.He saw how the pony was careful to lie down on different sides so she didnt seem to get sores, and how she allowed people to handle her.She protected her injured leg. She constantly shifted her weight and didnt overload her good leg. She was a smart pony with a serious
HTF Market Intelligence released a new research report of 41 pages on title Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H1 2017 with detailed analysis, forecast and strategies. The study covers key regions and important players such as KAHR medical Ltd, Silence Therapeutics Plc
The tumor necrosis factor (TNF) ligand and receptor superfamilies play an important role in cell proliferation, survival, and death. Stimulating or inhibiting TNF superfamily signaling pathways is expected to have therapeutic benefit for patients with various diseases, including cancer, autoimmunity, and infectious diseases. We review our current understanding of the structure and geometry of TNF superfamily ligands, receptors, and their interactions. A trimeric ligand and three receptors, each binding at the interface of two ligand monomers, form the basic unit of signaling. Clustering of multiple receptor subunits is necessary for efficient signaling. Current reports suggest that the receptors are prearranged on the cell surface in a "nonsignaling," resting state in a large hexagonal structure of antiparallel dimers. Receptor activation requires ligand binding, and cross-linking antibodies can stabilize the receptors, thereby maintaining the active, signaling state. On the other hand, an ...
View mouse Tnfrsf18 Chr4:156026164-156028895 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
View mouse Tnfrsf13b Chr11:61126755-61149372 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
These reference sequences exist independently of genome builds. Explain. These reference sequences are curated independently of the genome annotation cycle, so their versions may not match the RefSeq versions in the current genome build. Identify version mismatches by comparing the version of the RefSeq in this section to the one reported in Genomic regions, transcripts, and products above. ...
The KOMP Repository is located at the University of California Davis and Childrens Hospital Oakland Research Institute. Question? Comments? For Mice, Cells, and germplasm please contact us at [email protected], US 1-888-KOMP-MICE or International +1-530-752-KOMP, or for vectors [email protected] or +1-510-450-7917 ...
The KOMP Repository Collection is located at the MMRRC at the University of California, Davis and Childrens Hospital Oakland Research Institute. Question? Comments? For Mice, Cells, and germplasm please contact us at [email protected], US 1-888-KOMP-MICE or International +1-530-752-KOMP, or for vectors [email protected] or +1-510-450-7917 ...
[65 Pages Report] Check for Discount on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018 report by Global Markets Direct. Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or...
The tumor necrosis factor (TNF) superfamily refers to a superfamily of cytokines that can cause cell death (apoptosis). The first two members of the family to be identified were: Tumor necrosis factor (TNF), formerly known as TNFα or TNF alpha, is the best-known member of this class. TNF is a monocyte-derived cytotoxin that has been implicated in tumor regression, septic shock, and cachexia. The protein is synthesized as a prohormone with an unusually long and atypical signal sequence, which is absent from the mature secreted cytokine. A short hydrophobic stretch of amino acids serves to anchor the prohormone in lipid bilayers. Both the mature protein and a partially processed form of the hormone can be secreted after cleavage of the propeptide. Lymphotoxin-alpha, formerly known as Tumor necrosis factor-beta (TNF-β), is a cytokine that is inhibited by interleukin 10. Nineteen proteins have been identified as part of the TNF family on the basis of sequence, functional, and structural ...
Thank you for your interest in spreading the word about Science Signaling.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Tumor necrosis factor receptor superfamily, member 19, also known as TNFRSF19 and TROY is a human gene. The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is highly expressed during embryonic development. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. This receptor is capable of inducing apoptosis by a caspase-independent mechanism, and it is thought to play an essential role in embryonic development. Alternatively, spliced transcript variants encoding distinct isoforms have been described. GRCh38: Ensembl release 89: ENSG00000127863 - Ensembl, May 2017 GRCm38: Ensembl release 89: ENSMUSG00000060548 - Ensembl, May 2017 "Human PubMed Reference:". "Mouse PubMed Reference:". "Entrez Gene: TNFRSF19 tumor necrosis factor receptor superfamily, member 19". Robertson NG, Khetarpal U, Gutiérrez-Espeleta GA, et al. (1995). "Isolation of novel and known genes from a human fetal cochlear ...
Reagents, Tools and Custom Services for molecular biology, specializing in the fields of Nano-Antibody development (nAb), Cellular Reprogramming (iPSC), Genome Editing, Fluorescent Proteins, RNAi, Viral Packaging and Protein expression.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
The mouse monoclonal antibody recognizes human Integrin alpha L/CD11a. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain.
A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS ...
OPG antibody [13H21] (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)) for WB. Anti-OPG mAb (GTX53424) is tested in Mouse samples. 100% Ab-Assurance.
Das grundlegende Problem in der Transplantationsimmunologie ist es, die Langzeitakzeptanz eines fremden (allogen) Organs zu erreichen, ohne die sonstige Immunkompetenz des Empfängers zu beeinträchtigen. Die Induktion einer solchen spenderspezifischen Toleranz würde eine Alternative zum Langzeiteinsatz von Immunsuppressiva darstellen. Deswegen versucht man, während der Transplantation die Aktivierung der für die Abstoßung entscheidenden T-Helferzellen zu unterdrücken, bis eine Akzeptanz des Spenderorgans etabliert ist. Wichtig für eine Aktivierung der T-Zellen ist das für alle T-Helferzellen typische Zelloberflächenmolekül CD4. Antikörper gegen CD4 können in Tiermodellen eine Transplantattoleranz induzieren. Ein besonderes Interesse gilt der Charakterisierung der genauen Mechanismen dieser induzierten Transplantatakzeptanz, da diese noch wenig verstanden sind. Der von uns verwendete nicht-depletierende Maus-anti-Ratten-CD4mAk (RIB5/2) besitzt im allogenen Nierentransplantationsmodell ...
Gentaur molecular products has all kinds of products like :search , ATGen \ TNFSF11, 140-317aa, Human, His tag, E.coli \ ATGP1093 for more molecular products just contact us
|p|Tumor necrosis factor receptor superfamily, member 1A is a member of the Tumor necrosis factor receptor superfamily, which also contains TNFRSF1B. This protein is one of the major receptors for the tumor necrosis factor-alpha. This receptor can activate the transcription factor NF-kB, mediate apoptosis, and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the human genetic disorder called periodic fever syndrome. Impaired receptor clearance is thought to be a mechanism of the disease.|/p|
RPB499Hu01, CD120A; P55; TBP1; FPF; TNF-R; TNF-R-I; TNF-R55; TNFAR; TNFR1; TNFR55; TNFR60; P55-R; P60; Tumor necrosis factor receptor 1; Tumor necrosis factor-binding protein 1 | Products for research use only!
The TNFRSF11A gene encodes a member of the TNF receptor family and is therefore involved in regulation of immunen processes. Mutations cause autosomal recessive juvenile Paget disease, osteopetrosis, and dominant familial expansile osteolysis.. ...
A transmembrane protein belonging to the Tumor Necrosis Factor superfamily that was originally discovered on Cells of the lymphoid-myeloid lineage, including activated T-Lymphocytes and Natural Killer Cells. It plays an important Role in immune Homeostasis and Cell-mediated toxicity by binding to the fas Receptor and triggering Apoptosis ...
Tnfsf11 - Tnfsf11 (GFP-tagged) - Mouse tumor necrosis factor (ligand) superfamily member 11 (Tnfsf11), (10ug) available for purchase from OriGene - Your Gene Company.
This gene encodes a member of the TNF (tumor necrosis factor) receptor superfamily. The encoded protein functions in signal transduction pathways that activate inflammatory and inhibitory T-cell immune response. It binds herpes simplex virus (HSV) viral envelope glycoprotein D (gD), mediating its entry into cells. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014 ...
Research proven purified goat polyclonal TRAIL R3, DcR 1 or CD263 antibody. DcR1 is attached to the cell surface through glycophospholipid anchor. It has the extracellular TRAIL binding domain but lacks the cytoplasmic domain to induce apoptotic signal. Hence overexpression of DcR1 inhibits the TRAIL induced apoptosis. Designed for immunohistochemistry, western blotting, ELISA and related apllications. IHC image in product description.
Somatic mutations of the tumor suppressor tumor necrosis factor receptor superfamily member 14 (HVEM, encoded by TNFRSF14), which frequently occur in follicular lymphomas (FL), disrupt the interaction between HVEM and the immune checkpoint protein B and T lymphocyte associated (BTLA), resulting in the inhibition of T-cell immune responses. To elucidate the role of HVEM in germinal center (GC) lymphomagenesis, Boice, Salloum, Mourcin, and colleagues evaluated the interaction between HVEM and BTLA in FLs. Genomic and immunohistochemical analyses of human FLs identified HVEM mutations in 28% (40 of 141) of patient samples and the mutually exclusive loss of either HVEM or BTLA expression in 73% (145 of 198) of patient samples. Depletion of B cell-specific Hvem or Btla in a genetically engineered mouse model of FL resulted in enhanced lymphomagenesis in Hvem-deficient mice and Btla-deficient mice compared to control mice. Further, the morphology and activated status of the B-cell receptor (BCR) ...
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a - Market research report and industry analysis - 12355963
WORKLIST ENTRIES (1): TNFACTORR14 View alignment Tumour necrosis factor receptor 14 signature Type of fingerprint: COMPOUND with 4 elements Links: PRINTS; PR01918 TNFACTORR1A; PR01919 TNFACTORR1B; PR01920 TNFACTORR3 PRINTS; PR01921 TNFACTORR4; PR01922 TNFACTORR5; PR01680 TNFACTORR6 PRINTS; PR01960 TNFACTORR7; PR01923 TNFACTORR8; PR01924 TNFACTORR9 PRINTS; PR01956 TNFACTORR10; PR01961 TNFACTORR11; PR01962 TNFACTORR12 PRINTS; PR01963 TNFACTORR13B; PR01964 TNFACTORR13C; PR01966 TNFACTORR16 PRINTS; PR01967 TNFACTORR17; PR01968 TNFACTORR18; PR01969 TNFACTORR19 PRINTS; PR01970 TNFACTORR19l; PR01971 TNFACTORR21; PR01972 TNFACTORR25 PRINTS; PR01973 TNFACTORR27 PRINTS; PR01974 TNFACTORR11A; PR01975 TNFACTORR11B MIM; 602746 Creation date 23-JUN-2009 1. ARMITAGE, R. Tumor necrosis factor receptor superfamily members and their ligands. CURR.OPIN.IMMUNOL. 6 407-413 (1994). 2. BANNER D., DARCY, A., JAMES, W., GENTZ, R., SCHOENFELD, H., BROGER, C., LOETSCHER, H. AND LESSLAUER, W. Crystal structure of the ...
GITR Ligand/TNFSF18 products available through Novus Biologicals. Browse our GITR Ligand/TNFSF18 product catalog backed by our Guarantee+.

CD30 Ligand | Harvard Catalyst Profiles | Harvard CatalystCD30 Ligand | Harvard Catalyst Profiles | Harvard Catalyst

"CD30 Ligand" by people in Harvard Catalyst Profiles by year, and whether "CD30 Ligand" was a major or minor topic of these ... Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia. 1994 Dec; 8(12):2083-94. ... "CD30 Ligand" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "CD30 Ligand" by people in Profiles. ...
more infohttps://connects.catalyst.harvard.edu/Profiles/display/Concept/CD30%20Ligand

Buy Recombinant Human CD30 Ligand, Sf9 Protein (cyt-954)Buy Recombinant Human CD30 Ligand, Sf9 Protein (cyt-954)

Recombinant Human CD30 Ligand, Sf9 from Prospec cat# cyt-954. ProteoGenix provides you the best Cytokines and growth factors ... Proteins>Cytokines and growth factors proteins>Recombinant Human CD30 Ligand, Sf9 Protein ...
more infohttps://www.proteogenix-products.com/924-tnfsf8-sf9.html

Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions
							| European Journal of Histochemistry
			Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions | European Journal of Histochemistry

... the distinctive expression of CD30/CD30- L in deciduas from physiological pregnancies may indicate that the CD30/CD30-L system ... Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions. European Journal of Histochemistry, 49(3), 285 ... of CD30 and CD30-L and their cellular pattern detected in the deciduas from spontaneous abortions suggest that the CD30/CD30-L ... Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions https://doi.org/10.4081/955 ...
more infohttps://www.ejh.it/index.php/ejh/article/view/955

Patent US7718400 - Methods of increasing lean tissue mass using OB protein compositions - Google PatentsPatent US7718400 - Methods of increasing lean tissue mass using OB protein compositions - Google Patents

CD30 ligand. US5514582. Jan 21, 1994. May 7, 1996. Genentech, Inc.. Recombinant DNA encoding hybrid immunoglobulins. ... Chimeric ligand/immunoglobulin molecules and their uses. US5428130. Dec 8, 1992. Jun 27, 1995. Genentech, Inc.. Hybrid ... Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding," J Biol Chem. (1992) 267: ... phylogenetic conservation of receptor-ligand interaction," vol. 42(2), 235-247 (1995). (Abstract.).. ...
more infohttp://www.google.com/patents/US7718400?dq=3657699

Patent US7601814 - Reducing the immunogenicity of fusion proteins - Google PatentsPatent US7601814 - Reducing the immunogenicity of fusion proteins - Google Patents

CD30 ligand. US5514582. 21 Jan 1994. 7 May 1996. Genentech, Inc.. Recombinant DNA encoding hybrid immunoglobulins. ... of a ligand to a protein where it is already known that the ligand successfully binds to the protein and the protein/ligand ... The ligand, in the form of the consecutive amino acids of the peptide to be examined grafted onto a backbone from the backbone ... Thus, the ligand is a selected stretch of amino acids about 9 to 20 amino acids in length derived from a peptide, polypeptide ...
more infohttp://www.google.ca/patents/US7601814

Patente US7169904 - Immunocytokine sequences and uses thereof - Google PatentesPatente US7169904 - Immunocytokine sequences and uses thereof - Google Patentes

CD30 ligand. US5514582. 21 Ene 1994. 7 May 1996. Genentech, Inc.. Recombinant DNA encoding hybrid immunoglobulins. ... Chimeric ligand/immunoglobulin molecules and their uses. US5359035. 19 Oct 1992. 25 Oct 1994. Hoechst Aktiengesellschaft. ... Methods of stimulating hematopoietic cells with flt3-ligand. US5854205. 22 Oct 1996. 29 Dic 1998. The Childrens Medical Center ... Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," Journal of Biological Chemistry, ...
more infohttp://www.google.es/patents/US7169904?dq=flatulence

Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.

Soluble CD30 (sCD30) is a suggested marker for kidney transplantation outcomes. We investigated whether sCD30 serum levels are ... Cd30 Ligand. A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically ... Summary of "Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.". Soluble CD30 (sCD30) ... Antigens, Cd30. A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B ...
more infohttps://www.bioportfolio.com/resources/pmarticle/2020345/Influence-of-immunosuppressive-drugs-on-the-CD30-molecule-in-kidney-transplanted-patients.html

Tumour necrosis factor-like domain superfamily (IPR008983) | InterPro | EMBL-EBITumour necrosis factor-like domain superfamily (IPR008983) | InterPro | EMBL-EBI

Tumour necrosis factor family protein, CD30 ligand type (IPR021185). *Complement C1q subcomponent subunit A (IPR037572) ... Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.. J. Biol. Chem. 277 6631-6 2002 ... 2 A crystal structure of an extracellular fragment of human CD40 ligand.. Structure 3 1031-9 1995 ... the RANK ligand (TNFSF11), which triggers osteoclastogenesis via the RANK receptor [PMID: 11733492]; and TALL-1 (soluble domain ...
more infohttps://www.ebi.ac.uk/interpro/entry/IPR008983

KAKEN - Research Projects | 2010  Fiscal Year Final Research Report (KAKENHI-PROJECT-20390273)KAKEN - Research Projects | 2010 Fiscal Year Final Research Report (KAKENHI-PROJECT-20390273)

Journal Article] CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.2010. *. Author(s). Sun, X., Yamada, H ... Journal Article] CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses./CD30 ...
more infohttps://kaken.nii.ac.jp/en/report/KAKENHI-PROJECT-20390273/20390273seika/

US6680057B1 - Methods of treating autoimmune disease by administering interleukin-17 receptor 
        - Google PatentsUS6680057B1 - Methods of treating autoimmune disease by administering interleukin-17 receptor - Google Patents

Antibodies directed against CD30 ligand Legal Events. Date. Code. Title. Description. 2007-06-22. FPAY. Fee payment. Year of ... CD40 ligand polypeptide US7078494B1 (en) 2006-07-18. Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 ... A ligand (i.e., IL-17 or HVS-13) may also be used to prepare an affinity matrix for affinity purification of IL-17R. ... Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of ...
more infohttps://patents.google.com/patent/US6680057B1/en

US20040142095A1 - Nucleic acid arrays and method for detecting nucleic acids by using nucleic acid arrays 
        - Google...US20040142095A1 - Nucleic acid arrays and method for detecting nucleic acids by using nucleic acid arrays - Google...

Homo sapiens CD30 ligand mRNA. L11353. Human moesin-ezrin-radixin-like protein mRNA. ... Aptamer base technique for ligand identification US20030077595A1 (en) 2003-04-24. Methods and compositions for enhancing ... Methods and compositions for detecting binding of ligand pair using non-fluorescent label ...
more infohttps://patents.google.com/patent/US20040142095

Tnfsf8 MGI Mouse Gene Detail - MGI:88328 - tumor necrosis factor (ligand) superfamily, member 8Tnfsf8 MGI Mouse Gene Detail - MGI:88328 - tumor necrosis factor (ligand) superfamily, member 8

J:12921 Smith CA, et al., CD30 antigen, a marker for Hodgkins lymphoma, is a receptor whose ligand defines an emerging family ... J:200593 Guo Y, et al., CD30 Is Required for Activation of a Unique Subset of Interleukin-17A-Producing gammadelta T Cells in ...
more infohttp://www.informatics.jax.org/marker/MGI:88328

Recombinant Human TNFSF8, FLAG-tagged TNFSF8-2076H - Creative BioMartRecombinant Human TNFSF8, FLAG-tagged TNFSF8-2076H - Creative BioMart

CD30-L; CD30L; CD30LG; MGC138144; CD153 antigen; CD30 antigen ligand; CD30 ligand; OTTHUMP00000022762. ... This cytokine is a ligand for TNFRSF8/CD30, which is a cell surface antigen and a marker for Hodgkin lymphoma and related ... TNFSF8 tumor necrosis factor (ligand) superfamily, member 8 [ Homo sapiens ]. Synonyms:. TNFSF8; tumor necrosis factor (ligand ... The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. ...
more infohttps://www.creativebiomart.net/description_7044_12.htm

cleaved cell lymphoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginecleaved cell lymphoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

CD30 Ligand. CD40 Ligand / pharmacology. Carrier Proteins / pharmacology. Caspase 9. Caspases / metabolism. Cell Line, Tumor. ... Such constitutive CD30 cleavage is enhanced after binding of most anti-CD30 antibodies, leading to a downregulation of CD30 and ... CD30 Ligand; 0 / Carrier Proteins; 0 / Chromones; 0 / Membrane Glycoproteins; 0 / Morpholines; 0 / RANK Ligand; 0 / Receptor ... Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism ...
more infohttp://www.bmlsearch.com/?kwr=cleaved+cell+lymphoma+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

Concurrent Hodgkins Disease (Mixed Cellularity Type) and T-Cell Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia |...Concurrent Hodgkin's Disease (Mixed Cellularity Type) and T-Cell Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia |...

Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.Blood. 1994;83:2045-2056.PubMedGoogle ... CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.Blood. 1997;89:2048-2059 ... Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.Blood. 1995;85:3378-3404.PubMed ... BerH2/CD30+, L26/PanB−, UCHL-1/CD45RO−, cyCD3−, CD4−, CD8−, CD20−, CD79a−, EMA−, EBER-1+, LMP-1+. Southern blot analysis of the ...
more infohttps://link.springer.com/article/10.1007/BF02981943

TNFSF8 monoclonal antibody (M03), clone 3G9 - (H00000944-M03) - Products - AbnovaTNFSF8 monoclonal antibody (M03), clone 3G9 - (H00000944-M03) - Products - Abnova

This cytokine is a ligand for TNFRSF8/CD30, which is a cell surface antigen and a marker for Hodgkin lymphoma and related ... The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. ...
more infohttp://www.abnova.com/products/products_detail.asp?catalog_id=H00000944-M03

OX40 Ligand/TNFSF4 Antibody (MM0505-8S23) [DyLight 405] (NBP2-11969V): Novus BiologicalsOX40 Ligand/TNFSF4 Antibody (MM0505-8S23) [DyLight 405] (NBP2-11969V): Novus Biologicals

Mouse Monoclonal Anti-OX40 Ligand/TNFSF4 Antibody (MM0505-8S23) [DyLight 405]. Validated: Flow, IHC, IHC-Fr. Tested Reactivity ... Additional OX40 Ligand/TNFSF4 Products. OX40 Ligand/TNFSF4 NBP2-11969V * OX40 Ligand/TNFSF4 Antibodies ... Home » OX40 Ligand/TNFSF4 » OX40 Ligand/TNFSF4 Antibodies » OX40 Ligand/TNFSF4 Antibody (MM0505-8S23) [DyLight 405] ... Blogs on OX40 Ligand/TNFSF4. There are no specific blogs for OX40 Ligand/TNFSF4, but you can read our latest blog posts. ...
more infohttps://www.novusbio.com/products/ox40-ligand-tnfsf4-antibody-mm0505-8s23_nbp2-11969v

Table of Contents - September 01, 2004, 173 (5) | The Journal of ImmunologyTable of Contents - September 01, 2004, 173 (5) | The Journal of Immunology

CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease Bruce R. Blazar, Robert B. Levy, ... n-Nonanoyl-CC Chemokine Ligand 14, a Potent CC Chemokine Ligand 14 Analogue That Prevents the Recruitment of Eosinophils in ... 15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits IFN-Inducible Protein 10/CXC Chemokine Ligand 10 Expression in Human Microglia: ... Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus ...
more infohttp://www.jimmunol.org/content/173/5

Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohns diseaseInduction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease

CD30 Ligand/CD30 Interaction Is Involved in Pathogenesis of Inflammatory Bowel Disease. Somada, Shinichi; Muta, Hiromi; ... Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic... ... Background and Aims: Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as ... and the expression of Fas/Fas ligand and perforin in the inflamed and non- inflamed intestinal... ...
more infohttp://connection.ebscohost.com/c/articles/18384793/induction-t-lymphocyte-apoptosis-by-sulphasalazine-patients-crohns-disease

Shop | Page 123 of 128 | ReprokineShop | Page 123 of 128 | Reprokine

Optimized DNA sequence encoding Rat CD30 Ligand was expressed in HEK293 cells. Molecular weight:: Recombinant CD30 Ligand ( ...
more infohttps://reprokine.com/shop/page/123/

Frontiers | Mast Cells as Cellular Sensors in Inflammation and Immunity | ImmunologyFrontiers | Mast Cells as Cellular Sensors in Inflammation and Immunity | Immunology

... like TLR-ligands, CD30 ligand or vitamin D, selectively activate mast cells to release particular sets of cytokines (Marshall, ... Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J. ... TLR3 ligands or Newcastle disease virus induced anti-viral IFN-β and chemokine release and induced the recruitment of cytotoxic ... of Fc receptors that function as signaling modules that relay the antigen binding specificity of immunoglobulin ligands. This ...
more infohttps://www.frontiersin.org/articles/10.3389/fimmu.2011.00037/full

Association of Kaposis Sarcoma-Associated Herpesvirus-Positive Primary Effusion Lymphoma With Expression of the CD138/Syndecan...Association of Kaposi's Sarcoma-Associated Herpesvirus-Positive Primary Effusion Lymphoma With Expression of the CD138/Syndecan...

Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkins disease cell line. Blood 1996;88: ... differences in the size and composition of glycosaminoglycan chains have been previously suggested to reflect different ligand ...
more infohttp://www.bloodjournal.org/content/90/12/4894?ijkey=423ed65bb94c16ad8977b8a39ece2eb999c1557b&keytype2=tf_ipsecsha&sso-checked=true

Recombinant Cynomolgus TNFSF8 cell lysate TNFSF8-1190CCL - Creative BioMartRecombinant Cynomolgus TNFSF8 cell lysate TNFSF8-1190CCL - Creative BioMart

Cynomolgus CD30 Ligand / TNFSF8 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all ... Cynomolgus CD30 Ligand / TNFSF8 derived in Human Cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all ...
more infohttps://www.creativebiomart.net/description_398961_318.htm

TNFRSF8 Gene - GeneCards | TNR8 Protein | TNR8 AntibodyTNFRSF8 Gene - GeneCards | TNR8 Protein | TNR8 Antibody

Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population. (PMID: 11960307) Ahmed S ... Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the ... T Cell Co-Signaling Pathway: Ligand-Receptor Interactions. T Cell Co-Signaling Pathway: Ligand-Receptor Interactions ... T Cell Co-Signaling Pathway: Ligand-Receptor Interactions. *TNF Superfamily Pathway: Human Ligand-Receptor Interactions and ...
more infohttp://www.genecards.org/cgi-bin/carddisp.pl?gene=TNFRSF8&origene_full_trans=4

PromoKine - Recombinant HumanPromoKine - Recombinant Human

Recombinant Human CD30 Ligand (CHO cell-derived). 50 µg. C-63402. CD31 (PECAM-1), human, recombinant (HEK). Recombinant Human ... sCD40 Ligand (CD154), human, recombinant. Recombinant Human soluble CD40 Ligand (TRAP, CD154). 50 µg. C-63100. ... Recombinant Human CD27 Ligand (CHO cell-derived). 50 µg. C-63400. CD30L, human, recombinant (CHO). ... Recombinant Human 4-1BB Ligand (CD137L). 20 µg. C-66550. CD100, human, recombinant (CHO). Recombinant Human CD100 (Semaphorin; ...
more infohttps://www.promokine.info/products/cytokines-growth-factors/cd-antigens-cell-surface-markers/recombinant-human/
  • The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. (creativebiomart.net)
  • To investigate the impact of abrogation of OX40 and CD30 signals on the development of autoimmunity in FoxP3 KO mice, male C57BL/6 mice, deficient in both OX40 and CD30 (double [d] KO), were crossed with females with a heterozygous null allele for the X-linked gene FoxP3 (FoxP3 het ). (rupress.org)
  • There are currently no images for OX40 Ligand/TNFSF4 Antibody (NBP2-11969V). (novusbio.com)
  • This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with human TNFSF4, also called OX40 ligand. (novusbio.com)
  • Our previous studies have implicated signaling through the tumor necrosis family receptors OX40 and CD30 as critical for maintaining CD4 memory responses. (rupress.org)
  • However, in the combined absence of OX40 and CD30, FoxP3-deficient mice develop normally and breed successfully. (rupress.org)
  • Although the absence of OX40 plays the dominant role, FoxP3-deficient mice sufficient in CD30 but deficient in OX40 signals still eventually develop lethal disease. (rupress.org)
  • This result was supported by the observation that blocking antibodies to OX40 and CD30 ligands also abrogated disease mediated by FoxP3-deficient T cells. (rupress.org)
  • These observations identify OX40 and CD30 signals as essential for the development of clinically relevant CD4-dependent autoimmunity and suggest that combination therapies that abrogate these signals might be used to treat established human autoimmune diseases. (rupress.org)
  • We show in this paper that FoxP3 T reg cells are dispensable in mice deficient in OX40 and CD30 signals. (rupress.org)
  • FoxP3-deficient mice lacking OX40 and CD30 develop and grow normally, fail to develop clinically relevant autoimmune disease, and have a normal lifespan. (rupress.org)
  • We also show that blocking mAbs to OX40 and CD30 ligands abrogates development of FoxP3 KO disease. (rupress.org)
  • As expected, ∼50% of male offspring heterozygous for expression of OX40 and CD30 (dKO het ) were FoxP3 deficient and developed lethal autoimmune disease at ∼4 wk ( Fig. 1 A ), characterized by weight loss ( Fig. 1 B ) and scurfy phenotype ( Fig. 1 C ). Because OX40 and CD30 are linked genetically, offspring have a high probability of inheriting deficiency in both genes as a haplotype. (rupress.org)
  • The reduced expression of CD30 and CD30-L and their cellular pattern detected in the deciduas from spontaneous abortions suggest that the CD30/CD30-L system is crucial for preventing abortions in the first trimester. (ejh.it)
  • And furthermore, the distinctive expression of CD30/CD30- L in deciduas from physiological pregnancies may indicate that the CD30/CD30-L system exerts its main role in the first trimester. (ejh.it)
  • We investigated apoptosis in distinct mucosal compartments, and the expression of Fas/Fas ligand and perforin in the inflamed and non- inflamed intestinal. (ebscohost.com)
  • CD30 is the target of the FDA approved therapeutic brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. (wikipedia.org)
  • It is approved for use in: Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT) HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen CD30 has been shown to interact with TRAF5, TRAF1, TRAF2 and TRAF3. (wikipedia.org)
  • Journal Article] CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. (nii.ac.jp)
  • This graph shows the total number of publications written about "CD30 Ligand" by people in Harvard Catalyst Profiles by year, and whether "CD30 Ligand" was a major or minor topic of these publication. (harvard.edu)
  • Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. (ebi.ac.uk)